Immunotherapy for metastatic colorectal cancer: Present status and new options

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Immunotherapy for metastatic colorectal cancer : Present status and new options. / Ellebaek, Eva; Andersen, Mads Hald; Svane, Inge Marie; Straten, Per Thor.

I: Scandinavian Journal of Gastroenterology, Bind 47, Nr. 3, 2012, s. 315-24.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Ellebaek, E, Andersen, MH, Svane, IM & Straten, PT 2012, 'Immunotherapy for metastatic colorectal cancer: Present status and new options', Scandinavian Journal of Gastroenterology, bind 47, nr. 3, s. 315-24. https://doi.org/10.3109/00365521.2012.640831

APA

Ellebaek, E., Andersen, M. H., Svane, I. M., & Straten, P. T. (2012). Immunotherapy for metastatic colorectal cancer: Present status and new options. Scandinavian Journal of Gastroenterology, 47(3), 315-24. https://doi.org/10.3109/00365521.2012.640831

Vancouver

Ellebaek E, Andersen MH, Svane IM, Straten PT. Immunotherapy for metastatic colorectal cancer: Present status and new options. Scandinavian Journal of Gastroenterology. 2012;47(3):315-24. https://doi.org/10.3109/00365521.2012.640831

Author

Ellebaek, Eva ; Andersen, Mads Hald ; Svane, Inge Marie ; Straten, Per Thor. / Immunotherapy for metastatic colorectal cancer : Present status and new options. I: Scandinavian Journal of Gastroenterology. 2012 ; Bind 47, Nr. 3. s. 315-24.

Bibtex

@article{9885d81b50ec42f0afb0da8badb07149,
title = "Immunotherapy for metastatic colorectal cancer: Present status and new options",
abstract = "Although no immunotherapeutic treatment is approved for colorectal cancer (CRC) patients, promising results from clinical trials suggest that several immunotherapeutic strategies may prove efficacious and applicable to this group of patients. This review describes the immunogenicity of CRC and presents the most interesting strategies investigated so far: cancer vaccination including antigen-defined vaccination and dendritic cell vaccination, chemo-immunotherapy, and adoptive cell transfer. Future treatment options as well as the possibility of combining existing therapies will be discussed along with the challenges presented by tumor escape mechanisms.",
author = "Eva Ellebaek and Andersen, {Mads Hald} and Svane, {Inge Marie} and Straten, {Per Thor}",
year = "2012",
doi = "10.3109/00365521.2012.640831",
language = "English",
volume = "47",
pages = "315--24",
journal = "Scandinavian Journal of Gastroenterology",
issn = "0036-5521",
publisher = "Taylor & Francis",
number = "3",

}

RIS

TY - JOUR

T1 - Immunotherapy for metastatic colorectal cancer

T2 - Present status and new options

AU - Ellebaek, Eva

AU - Andersen, Mads Hald

AU - Svane, Inge Marie

AU - Straten, Per Thor

PY - 2012

Y1 - 2012

N2 - Although no immunotherapeutic treatment is approved for colorectal cancer (CRC) patients, promising results from clinical trials suggest that several immunotherapeutic strategies may prove efficacious and applicable to this group of patients. This review describes the immunogenicity of CRC and presents the most interesting strategies investigated so far: cancer vaccination including antigen-defined vaccination and dendritic cell vaccination, chemo-immunotherapy, and adoptive cell transfer. Future treatment options as well as the possibility of combining existing therapies will be discussed along with the challenges presented by tumor escape mechanisms.

AB - Although no immunotherapeutic treatment is approved for colorectal cancer (CRC) patients, promising results from clinical trials suggest that several immunotherapeutic strategies may prove efficacious and applicable to this group of patients. This review describes the immunogenicity of CRC and presents the most interesting strategies investigated so far: cancer vaccination including antigen-defined vaccination and dendritic cell vaccination, chemo-immunotherapy, and adoptive cell transfer. Future treatment options as well as the possibility of combining existing therapies will be discussed along with the challenges presented by tumor escape mechanisms.

U2 - 10.3109/00365521.2012.640831

DO - 10.3109/00365521.2012.640831

M3 - Journal article

C2 - 22214467

VL - 47

SP - 315

EP - 324

JO - Scandinavian Journal of Gastroenterology

JF - Scandinavian Journal of Gastroenterology

SN - 0036-5521

IS - 3

ER -

ID: 48579825